Výsledky vyhledávání - "Shabnam, Zolfaghari"

Anticoagulation in patients with impaired renal function and with haemodialysis

Autor: Martin Wehling, B. K. Krämer, V. A.-T. Hentschel, Shabnam Zolfaghari, Roland Krämer, J. Harenberg, Christel Weiss, Shanshan Du

Publikováno v: Hämostaseologie. 35:77-83

SummaryPatients with impaired renal function are exposed to an increased risk for bleeding complications depending on the amount of the anticoagulant eliminated by the kidneys. The elimination of unfractionated heparins, vitamin K antagonists and arg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d7e6ac3dd7e6318124596c01707568
https://doi.org/10.5482/hamo-14-08-0036

Zobrazit plný text záznamu

Entwicklung eines Fragebogens zur Identifikation der Präferenz von Patienten für ein konventionelles oder ein direktes orales Antikoagulanz

Autor: Lutz Frölich, Job Harenberg, Martin Wehling, Shabnam Zolfaghari, Christel Weiss

Publikováno v: MMW - Fortschritte der Medizin. 156:107-114

Hintergrund: Eine orale Antikoagulation kann heute mit Vitamin-K-abhangigen (VKA) oder neuen, nicht Vitamin-K-abhangigen oralen Antikoagulanzien (NOAK) durchgefuhrt werden. Es ist daher moglich, Patienten in den Entscheidungsprozess zur Wahl des Anti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49b831778c71f873ff15df3e2930388d
https://doi.org/10.1007/s15006-014-3756-5

Zobrazit plný text záznamu

Klinische Studien zu neuen direkten oralen Antikoagulanzien

Autor: C. Weiss, Svetlana Marx, J. Harenberg, Shabnam Zolfaghari

Publikováno v: Phlebologie. 42:139-148

ZusammenfassungUm die Wirksamkeit und Verträglichkeit neuer direkter oraler Antikoagulanzien (DOAK) zu vergleichen, müssten idealerweise eine direkte Gegenüberstellung der Substanzen in klinischen Studien durchgeführt werden. Auf Grund des logist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2d953f402ddde09cee58a3c39990258
https://doi.org/10.12687/phleb2146-3-2013

Zobrazit plný text záznamu

Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study

Autor: Roland Krämer, Christel Weiss, Shabnam Zolfaghari, Job Harenberg, Shanshan Du, Jeanine M. Walenga, Martin Wehling

Publikováno v: Clinical Chemistry and Laboratory Medicine (CCLM). 54

The utility of measuring non-vitamin K antagonist oral anticoagulants (NOACs) in plasma, serum and urine samples and with the point-of-care test (POCT) on urine samples should be analysed in an international laboratory study.The study was performed t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8230b9f9d582b56918eb465d3b71d31a
https://doi.org/10.1515/cclm-2015-0389

Zobrazit plný text záznamu

[Development of a questionnaire to identify patients' preference for a conventional or a direct oral anticoagulant]

Autor: Shabnam, Zolfaghari, Job, Harenberg, Martin, Wehling, Lutz, Frölich, Christel, Weiss

Publikováno v: MMW Fortschritte der Medizin. 156

Oral anticoagulant therapy is currently performed using vitamin K-dependent (VKA) or novel, non-vitamin-K-dependent (NOAC) anticoagulants. Patients can thus be involved into the decision process which type of anticoagulants to use. Preference of pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::012199a39cb5f29b64fba68bcd3984fe
https://pubmed.ncbi.nlm.nih.gov/26153589

Zobrazit plný text záznamu

Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference

Autor: Martin Wehling, Christel Weiss, Shabnam Zolfaghari, Gregory Y.H. Lip, Jan Beyer-Westendorf, Lutz Frölich, Jürgen H. Prochaska, Job Harenberg, Philip Wild, Jürgen Koscielny

Publikováno v: Seminars in thrombosis and hemostasis. 41(2)

Patients with indication for anticoagulation may prefer treatment with a vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulant (NOAC). A questionnaire may help to identify the preference of patients for one of the two types of ora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c044bfe02e17867d19e12d2c5c116a82
https://pubmed.ncbi.nlm.nih.gov/25703522

Zobrazit plný text záznamu

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy

Autor: Christel Weiss, Job Harenberg, Lutz Froelich, Shabnam Zolfaghari, Martin Wehling

Publikováno v: Seminars in thrombosis and hemostasis. 40(1)

Direct oral anticoagulants (DOACs) were developed for the treatment of thromboembolic diseases to overcome limitations of vitamin K antagonists (VKA). International guidelines on atrial fibrillation acknowledge patients' for antiembolic therapy with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c488b1b4a21430a7c59ef48c1b3052b
https://pubmed.ncbi.nlm.nih.gov/24381153

Zobrazit plný text záznamu

Measurement of rivaroxaban and apixaban in serum samples of patients

Autor: Gregory Y.H. Lip, Shanshan Du, Sandra Krämer, Shabnam Zolfaghari, Job Harenberg, Martin Wehling, Christel Weiss, Roland Krämer, Astrid Schulze

Publikováno v: European Journal of Clinical Investigation

Background The determination of rivaroxaban and apixaban from serum samples of patients may be beneficial in specific clinical situations when additional blood sampling for plasma and thus the determination of factor Xa activity is not feasible or re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460b054b1b2d10fcd24cbb5a94f47746
https://pubmed.ncbi.nlm.nih.gov/24931429

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání